Work

The Promise of Selective PARP1 Inhibitors in Cancer Therapy

Year: 2025

Type: editorial

Abstract: High Resolution Image Download MS PowerPoint Slide Poly(ADP-ribose) polymerase 1 (PARP1) is a critical enzyme involved in the DNA damage response. The therapeutic inhibition of PARP1 has emerged as a promising strategy, particularly in cancers with homologous recombination deficiencies (HRDs). A recent report disclosed the discovery of ( S )-G9 as a selective PARP1 inhibitor for clinical development.

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.5c00561

Authors: Xin Zhou, Jimmy S. Patel, Taoqian Zhao, Steven H. Liang

Institution: Emory University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500